📷 Image: Wikimedia Commons / Post of India
Health
Price cuts of up to 70% announced for 137 cancer drugs from Nov 9
✍️ India Today
🗓 18 Oct 2026, 01:16 AM
👁 10
India will reduce the prices of 137 cancer medicines by as much as 70% starting November 9, according to India Today.
The Ministry of Health has approved a sweeping reduction in the retail prices of cancer medicines, affecting 137 different drugs. The new price structure will come into force on November 9, with discounts that can reach up to 70 percent compared with current rates.
The decision, reported by India Today, is part of a broader effort to make oncology treatment more affordable for patients across the country. While the exact percentage varies by product, the maximum cut of 70 percent applies to the most expensive formulations.
Industry analysts expect the move to ease the financial burden on cancer patients and their families, potentially improving treatment adherence. The price revision will be reflected in the National Pharmaceutical Pricing Authority’s database and will be enforced across all licensed pharmacies and hospitals.
The government has not disclosed any additional subsidies or insurance adjustments linked to the price cuts, but officials indicated that the policy aligns with ongoing health‑care affordability initiatives.
The decision, reported by India Today, is part of a broader effort to make oncology treatment more affordable for patients across the country. While the exact percentage varies by product, the maximum cut of 70 percent applies to the most expensive formulations.
Industry analysts expect the move to ease the financial burden on cancer patients and their families, potentially improving treatment adherence. The price revision will be reflected in the National Pharmaceutical Pricing Authority’s database and will be enforced across all licensed pharmacies and hospitals.
The government has not disclosed any additional subsidies or insurance adjustments linked to the price cuts, but officials indicated that the policy aligns with ongoing health‑care affordability initiatives.